NeoStem, Inc. Data From Phase 2 Preserve AMI Clinical Trial To Be Presented At American Heart Association Scientific Sessions On November 17
NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today scheduling details regarding upcoming presentations at the American Heart Association Scientific Sessions of data from its Phase 2 PreSERVE AMI clinical trial evaluating NBS10 in the treatment of damaged heart muscle following a heart attack. NeoStem also plans to issue a press release following the first presentation and conduct an investor conference call and webcast relating to the data on Tuesday, November 18th, at 8:00 AM EST.
American Heart Association Scientific Sessions 2014
- Exhibition Booth: 743
- Website: http://www.scientificsessions.org
Presentation 1
- Date and Time: Monday, November 17, 2014, 4:07 PM CST
- Venue: Room S100ab, McCormick Place, Chicago, Illinois
- Session: CS.02 – Off the Beaten Pathologies
- Topic: PreSERVE AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Infusion of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI
- Speaker: Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University, Lead Principal Investigator of PreSERVE AMI study
Presentation 2
- Date and Time: Tuesday, November 18, 2014, 8:00 AM CST
- Venue: Room S405, McCormick Place, Chicago, Illinois
- Session: CVS.517 – Use of Progenitor Cells to Improve Cardiac Remodeling
- Topic: Bone Marrow Cells and Patient Care
- Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
Investor Conference Call Details
- Date and Time: Tuesday, November 18, 2014, 8:00 AM EST
To access the webcast, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events or call 1-855-235-8282 and provide Conference ID 32811273. An archive of the call will be available approximately two hours after its completion. To access the archived recording, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events. The archive of the call will be available for 90 days following the call.
About NBS10
NBS10, also known as AMR-001, the Company's lead candidate in its ischemic repair program, is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack or AMI). The PreSERVE AMI Phase 2 trial is a 160 patient randomized, double-blind, placebo-controlled clinical trial evaluating NBS10 in patients with post ST segment elevation myocardial infarction (STEMI). Ischemia occurs when the supply of oxygenated blood in the body is restricted. NeoStem seeks to improve oxygen delivery to tissues through the development and formation of new blood vessels. NBS10 is designed to address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning NeoStem to capture a meaningful share of this worldwide market.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Cancer Immunotherapy Program, Ischemic Repair Program, Immune Modulation Program (particularly with respect to NBS10) and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: mrice@lifesciadvisors.com Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com 
Help employers find you! Check out all the jobs and post your resume.